Arrowhead Pharmaceuticals, INC. (ARWR) — 10-K Filings
All 10-K filings from Arrowhead Pharmaceuticals, INC.. Browse 2 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (2)
-
Arrowhead Launches First Commercial Drug, Eyes sHTG Expansion
— Nov 25, 2025 Risk: medium
Arrowhead Pharmaceuticals, Inc. (ARWR) achieved a significant milestone in 2025 with the FDA approval and commercial launch of REDEMPLO (plozasiran) for Familia - 10-K Filing — Nov 26, 2024
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX